Danaher Co. (NYSE:DHR) Shares Acquired by Fiduciary Trust Co

Fiduciary Trust Co boosted its position in shares of Danaher Co. (NYSE:DHR) by 12.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,047 shares of the conglomerate’s stock after purchasing an additional 5,623 shares during the period. Fiduciary Trust Co’s holdings in Danaher were worth $13,914,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Danaher by 1.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 301,039 shares of the conglomerate’s stock valued at $83,695,000 after acquiring an additional 3,673 shares in the last quarter. CreativeOne Wealth LLC lifted its stake in shares of Danaher by 24.7% in the third quarter. CreativeOne Wealth LLC now owns 1,542 shares of the conglomerate’s stock worth $429,000 after acquiring an additional 305 shares in the last quarter. BNP Paribas boosted its holdings in Danaher by 15.3% in the third quarter. BNP Paribas now owns 1,806 shares of the conglomerate’s stock valued at $502,000 after purchasing an additional 240 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Danaher by 48.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 67,639 shares of the conglomerate’s stock worth $18,805,000 after purchasing an additional 22,205 shares during the last quarter. Finally, Glenmede Trust Co. NA raised its position in shares of Danaher by 0.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 51,553 shares of the conglomerate’s stock valued at $14,333,000 after purchasing an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $238.90 on Thursday. The business has a 50 day simple moving average of $256.00 and a 200 day simple moving average of $259.66. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $172.55 billion, a price-to-earnings ratio of 45.59, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. Danaher Co. has a 12-month low of $215.68 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the business posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DHR shares. Stifel Nicolaus raised their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. KeyCorp upped their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Wells Fargo & Company began coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Finally, UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.